X

Jetzt Startbonus sichern: MSCI World ETF oder Gratis-Aktie geschenkt!

Unser Broker finanzen.net ZERO schenkt Dir einen Anteil am neuen Finanzen.net MSCI World ETF oder eine Gratis-Aktie!
Eröffne jetzt Dein Depot mit dem Promocode 'Startbonus2026'.

Jetzt kostenlos starten

Es gelten die Aktionsfristen und Teilnahmebedingungen.

Nicht mehr anzeigen

Personalis Aktie

Kaufen

Verkaufen

Personalis Aktien-Sparplan Personalis Aktien-Sparplan

7,21 EUR +0,21 EUR +2,93 %

18:03:58

STU

8,64 USD +0,28 USD +3,35 %

18:04:13

BTT

Personalis jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)

Bei einem anderen Broker handeln

Smartphone

Marktkap.666,46 Mio. EUR

Div. Rendite0,00%

WKNA2PLTK

ISINUS71535D1063

SymbolPSNL

Personalis Aktien News

Sortieren:Datum Meistgelesen

19.12.24BusinesswirePersonalis Advances Business Strategy with Investment from Merck and Extends Collaboration with Moderna

16.12.24BusinesswirePersonalis and Tempus Expand Collaboration to Biopharma

16.09.24BusinesswireESMO 2024 Data Expands on Compelling Performance of Personalis NeXT Personal® MRD Test

WerbungPersonalis-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

19.08.24BusinesswirePersonalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04.06.24BusinesswireASCO Data Highlights NeXT Personal® Ultra-sensitive MRD Performance in Early-stage Breast Cancer Recurrence Detection and Immunotherapy Monitoring

31.05.24BusinesswirePersonalis Announces Start of Cancer MRD Testing Commercialization Collaboration with Tempus

22.05.24BusinesswirePersonalis Announces Podium Presentations and Abstracts Accepted at ASCO 2024

17.05.24BusinesswirePersonalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

28.03.24BusinesswireData Showcasing NeXT Personal MRD Test to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting

26.03.24BusinesswirePersonalis Announces Publication Validating NeXT Personal® Test for Ultra-sensitive MRD Detection and Cancer Treatment Response Monitoring

19.03.24BusinesswirePersonalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

28.02.24BusinesswirePersonalis Reports Fourth Quarter and Full Year 2023 Financial Results

14.02.24BusinesswirePersonalis to Announce Fourth Quarter and Full Year 2023 Financial Results

30.01.24BusinesswirePersonalis and ClearNote Health Announce Partnership to Advance Epigenomic Technology

17.01.24BusinesswirePersonalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

16.01.24BusinesswirePersonalis Announces Medicare Coverage for NeXT Dx(R) Comprehensive Genomic Tumor Profiling Assay

05.01.24BusinesswirePersonalis Reports Preliminary Fourth Quarter and Full Year 2023 Revenue and Cash Balance

04.12.23BusinesswirePersonalis Extends Cash Position Into 2026, Provides Update on Key Initiatives

28.11.23BusinesswirePersonalis and Tempus Enter into a Strategic Collaboration to Advance Cancer Testing

26.10.23BusinesswirePersonalis Launches NeXT Personal® Dx for Early Access Clinical Use in Residual Disease and Recurrence Detection in Cancer

21.10.23BusinesswireAnalysis from TRACERx Study Reveals More Sensitive and Earlier ctDNA Detection in Lung Cancer Patients by Personalis' MRD Technology

19.10.23BusinesswirePersonalis Announces Late-Breaking NeXT Personal Abstract and Proffered Paper Presentation at ESMO 2023

18.10.23BusinesswirePersonalis Appoints Former Roche Diagnostics and GRAIL Executive Deepshikha Bhandari as SVP, Regulatory, Quality and Clinical Compliance

Personalis News

Personalis News: auf dieser Seite finden Sie alle Personalis News und Nachrichten zur Personalis Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Personalis News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Personalis News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.